1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid - Drugs In Development, 2022, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and burning sensation of the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatory and immunosuppressant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 1, 4, 1 and 1 respectively.
Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Bullous Pemphigoid - Overview
- Bullous Pemphigoid - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Bullous Pemphigoid - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bullous Pemphigoid - Companies Involved in Therapeutics Development
- Akari Therapeutics Plc
- Alkahest Inc
- Alpine Immune Sciences Inc
- Amgen Inc
- Argenx SE
- ARTham Therapeutics Inc
- Immungenetics AG
- Innate Pharma SA
- Kyowa Kirin Co Ltd
- Regeneron Pharmaceuticals Inc
- Regranion LLC
- Sanofi
- Satellos Bioscience Inc
- SFA Therapeutics Inc
- viDA Therapeutics Inc
- Bullous Pemphigoid - Drug Profiles
- ALPN-303 - Drug Profile
- Product Description
- Mechanism Of Action
- apremilast - Drug Profile
- Product Description
- Mechanism Of Action
- ART-648 - Drug Profile
- Product Description
- Mechanism Of Action
- avdoralimab - Drug Profile
- Product Description
- Mechanism Of Action
- benralizumab - Drug Profile
- Product Description
- Mechanism Of Action
- bertilimumab - Drug Profile
- Product Description
- Mechanism Of Action
- dimethyl fumarate - Drug Profile
- Product Description
- Mechanism Of Action
- dupilumab - Drug Profile
- Product Description
- Mechanism Of Action
- efgartigimod alfa - Drug Profile
- Product Description
- Mechanism Of Action
- lazucirnon hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- RGRN-305 - Drug Profile
- Product Description
- Mechanism Of Action
- SFA-003 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- sutimlimab - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Coversin - Drug Profile
- Product Description
- Mechanism Of Action
- VTI-1002 - Drug Profile
- Product Description
- Mechanism Of Action
- Bullous Pemphigoid - Dormant Projects
- Bullous Pemphigoid - Discontinued Products
- Bullous Pemphigoid - Product Development Milestones
- Featured News & Press Releases
- Jan 15, 2021: ARTham Therapeutics presents phase I results for ART-648 at ASCPT 2021 Annual Meeting
- Mar 30, 2020: ART-648 program was selected as a drug discovery project for orphan diseases to be supported by AMED
- Jan 20, 2020: AstraZeneca studies Fasenra in three new trials for skin diseases
- Sep 11, 2018: Bertilimumab granted Fast Track Designation for the treatment of Bullous Pemphigoid
- Aug 20, 2018: Bertilimumab granted Orphan Drug Designation for the treatment of Bullous Pemphigoid
- Jul 30, 2018: Immune Pharmaceuticals receives positive opinion for orphan drug designation in the European Union for Bertilimumab for the treatment of bullous pemphigoid
- May 15, 2018: Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
- Mar 12, 2018: Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium
- Sep 27, 2017: Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
- Aug 28, 2017: Immune Pharmaceuticals Provides update on bertilimumab
- Feb 28, 2017: Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid
- Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States
- Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid
- Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid
- Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Bullous Pemphigoid, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Bullous Pemphigoid - Pipeline by Akari Therapeutics Plc, 2022
- Bullous Pemphigoid - Pipeline by Alkahest Inc, 2022
- Bullous Pemphigoid - Pipeline by Alpine Immune Sciences Inc, 2022
- Bullous Pemphigoid - Pipeline by Amgen Inc, 2022
- Bullous Pemphigoid - Pipeline by Argenx SE, 2022
- Bullous Pemphigoid - Pipeline by ARTham Therapeutics Inc, 2022
- Bullous Pemphigoid - Pipeline by Immungenetics AG, 2022
- Bullous Pemphigoid - Pipeline by Innate Pharma SA, 2022
- Bullous Pemphigoid - Pipeline by Kyowa Kirin Co Ltd, 2022
- Bullous Pemphigoid - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Bullous Pemphigoid - Pipeline by Regranion LLC, 2022
- Bullous Pemphigoid - Pipeline by Sanofi, 2022
- Bullous Pemphigoid - Pipeline by Satellos Bioscience Inc, 2022
- Bullous Pemphigoid - Pipeline by SFA Therapeutics Inc, 2022
- Bullous Pemphigoid - Pipeline by viDA Therapeutics Inc, 2022
- Bullous Pemphigoid - Dormant Projects, 2022
- Bullous Pemphigoid - Discontinued Products, 2022
- Number of Products under Development for Bullous Pemphigoid, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akari Therapeutics Plc
- Alkahest Inc
- Alpine Immune Sciences Inc
- Amgen Inc
- Argenx SE
- ARTham Therapeutics Inc
- Immungenetics AG
- Innate Pharma SA
- Kyowa Kirin Co Ltd
- Regeneron Pharmaceuticals Inc
- Regranion LLC
- Sanofi
- Satellos Bioscience Inc
- SFA Therapeutics Inc
- viDA Therapeutics Inc
